Non steroidal anti inflammatory drugs has been found to have a major role in decreasing edema and inflammation of vessels wall and permit air entry to lung, what is the clinical parameter that indicate it is uses?
Low doses of dexamethasone could reduce the mortality in patients with severe COVID-19 disease. It has been proven to significantly reduce the mortality risk in COVID-19 patients on ventilation and oxygen by as much as 35% and 20%, respectively. However, no clinical benefits have been seen in patients with mild, moderate, and hospitalized COVID-19 patients, not on oxygen or ventilation.
Article Dexamethasone: A boon for critically ill COVID-19 patients?
Article Dexamethasone for the Treatment of Coronavirus Disease (COVI...
Role of Dexamethasone in patients with severe COVID-19
Dexamethasone in a dose of 6 mg daily as iv or orally for a maximum of 10 days has been shown to reduce the mortality by 35% in critically ill COVID-19 patients with ARDS on ventilator and by 20% in patients needing supplemental oxygen (1).
It has it's effect mainly to help in the inflammatory edema and is a strong immunosuppressant for COVID-19 patients with immune storm.
Dexamethasone is the strongest of the corticosteroids with 6 mg equivalent to 50 mg of prednisone or 200 mg of hydrocortisone (2).
1. Preprint Effect of Dexamethasone in Hospitalized Patients with COVID-...
2. https://clincalc.com/Corticosteroids/?example
It is not an effective treatment, but it can reduce complications in severe cases for the patient. It is a supportive treatment.
Covid-19 is usually a mild self-limiting illness that does not require any treatment.
Current evidence based medicine is based on the presumption of significance when P
Please see the links below.
https://www.nature.com/articles/d41586-020-01824-5
https://www.news-medical.net/news/20200616/Life-Saving-Drug-Found-for-COVID-19-Patients-on-Ventilators.aspx
Low doses of dexamethasone could reduce the mortality in patients with severe COVID-19 disease. It has been proven to significantly reduce the mortality risk in COVID-19 patients on ventilation and oxygen by as much as 35% and 20%, respectively. However, no clinical benefits have been seen in patients with mild, moderate, and hospitalized COVID-19 patients, not on oxygen or ventilation.
Article Dexamethasone: A boon for critically ill COVID-19 patients?
Article Dexamethasone for the Treatment of Coronavirus Disease (COVI...
Dear Ziad Hazim Deleme, please have a look at the link below:
Article Dexamethasone in Hospitalized Patients with Covid-19 — Preli...
Dear Ziad Hazim Deleme, you may go through the following link:
Article Dexamethasone in the management of covid -19
- Badges
- Science topic